{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T01:57:25Z","timestamp":1775699845254,"version":"3.50.1"},"reference-count":73,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Although various guidelines for cardiovascular disease prevention have been established, the optimal drug therapy is often not implemented due to poor medication adherence and the clinical inertia of healthcare practitioners. Polypill strategies are one solution to this problem. Previous studies have established the usefulness of polypills, i.e., combination tablets including three or more medications, for the prevention of cardiovascular disease. For this purpose, the polypills generally contain an antiplatelet medication, an antihypertensive medication, and a statin. For the specific management of hypertension, combination therapy including more than two classes of antihypertensive medications is recommended by most international guidelines. Combination tablets including two classes of antihypertensive medications, such as renin-angiotensin system (RAS) inhibitors (angiotensin-converting enzyme inhibitors [ACEIs] and angiotensin receptor blockers [ARBs]) and Ca-channel blockers or thiazide diuretics, have been reported to be useful for cardiovascular disease prevention and lowering blood pressure (BP) levels. The use of RAS inhibitors is recommended for a wide range of complications, including diabetes, chronic heart failure, and chronic kidney disease. The combination of an RAS inhibitor and diuretic or Ca-channel blocker is thus recommended for the management of hypertension. Finally, we expect that novel medications such as angiotensin receptor neprilysin inhibitors (ARNIs) and sodium glucose cotransporter 2 inhibitors (SGLT2i), which have a more diverse range of effects in hypertension, heart failure, or diabetes, may be a solution to the problem of polypharmacy. Evidence is accumulating on the benefits of polypill strategies in cardiovascular disease prevention. Combination tablets are also effective for the treatment of hypertension.<\/jats:p>","DOI":"10.3390\/jcm12237226","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T04:21:27Z","timestamp":1700626887000},"page":"7226","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Polypill Therapy for Cardiovascular Disease Prevention and Combination Medication Therapy for Hypertension Management"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2020-898X","authenticated-orcid":false,"given":"Keisuke","family":"Narita","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, Jichi Medical University School of Medicine, Shimotsuke 329-0498, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Hoshide","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, Jichi Medical University School of Medicine, Shimotsuke 329-0498, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuomi","family":"Kario","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, Jichi Medical University School of Medicine, Shimotsuke 329-0498, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1093\/eurheartj\/ehac395","article-title":"Hypertension management in patients with cardiovascular comorbidities","volume":"44","author":"Lauder","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","article-title":"The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)","volume":"42","author":"Umemura","year":"2019","journal-title":"Hypertens. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/jch.14075","article-title":"The feasibility of polypill for cardiovascular disease prevention in Asian Population","volume":"23","author":"Sukonthasarn","year":"2021","journal-title":"J. Clin. Hypertens."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1038\/s41440-023-01333-8","article-title":"Anti-hypertensive medication adherence in the REQUIRE trial: Post-hoc exploratory evaluation","volume":"46","author":"Kario","year":"2023","journal-title":"Hypertens. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1136\/bmj.326.7404.1419","article-title":"A strategy to reduce cardiovascular disease by more than 80%","volume":"326","author":"Wald","year":"2003","journal-title":"BMJ"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.cjca.2014.02.016","article-title":"Evolution of the Polypill Concept and Ongoing Clinical Trials","volume":"30","author":"Castellano","year":"2014","journal-title":"Can. J. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1185\/03007995.2011.555754","article-title":"Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: The CRUCIAL trial","volume":"27","author":"Zamorano","year":"2011","journal-title":"Curr. Med Res. Opin."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S0140-6736(17)30553-6","article-title":"Uses of polypills for cardiovascular disease and evidence to date","volume":"389","author":"Huffman","year":"2017","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0140-6736(19)31791-X","article-title":"Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): A pragmatic, cluster-randomised trial","volume":"394","author":"Roshandel","year":"2019","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1056\/NEJMoa2208275","article-title":"Polypill Strategy in Secondary Cardiovascular Prevention","volume":"387","author":"Castellano","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/heartjnl-2018-313108","article-title":"Reaching cardiovascular prevention guideline targets with a polypill-based approach: A meta-analysis of randomised clinical trials","volume":"105","author":"Selak","year":"2019","journal-title":"Heart"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijcard.2021.08.023","article-title":"Halving cardiovascular risk with combined blood pressure and cholesterol lowering \u2013 Why are we not there yet?","volume":"341","author":"Wang","year":"2021","journal-title":"Int. J. Cardiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1093\/eurheartj\/ehab919","article-title":"Polypill for prevention of cardiovascular diseases with focus on non-alcoholic steatohepatitis: The PolyIran-Liver trial","volume":"43","author":"Merat","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa2028220","article-title":"Polypill with or without Aspirin in Persons without Cardiovascular Disease","volume":"384","author":"Yusuf","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(21)01827-4","article-title":"Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: An individual participant data meta-analysis","volume":"398","author":"Joseph","year":"2021","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)","volume":"39","author":"Ibanez","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)","volume":"42","author":"Collet","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC)","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0140-6736(21)01922-X","article-title":"Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): A phase 3, randomised, double-blind, active-controlled trial","volume":"398","author":"Chow","year":"2021","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1268119","DOI":"10.3389\/fphar.2023.1268119","article-title":"Redefining the polypill: Pros and cons in cardiovascular precision medicine","volume":"14","author":"Birla","year":"2023","journal-title":"Front. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2013.277064","article-title":"Effects of a Fixed-Dose Combination Strategy on Adherence and Risk Factors in Patients with or at High Risk of CVD: The UMPIRE Randomized Clinical Trial","volume":"310","author":"Thom","year":"2013","journal-title":"JAMA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"g3318","DOI":"10.1136\/bmj.g3318","article-title":"Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: Randomised controlled trial in primary care","volume":"348","author":"Selak","year":"2014","journal-title":"BMJ"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/j.jacc.2014.08.021","article-title":"A Polypill Strategy to Improve Adherence: Results from the FOCUS project","volume":"64","author":"Castellano","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Fuster, V., Gamb\u00fas, F., Patriciello, A., Hamrin, M., and Grobbee, D.E. (2017). The polypill approach \u2013 An innovative strategy to improve cardiovascular health in Europe. BMC Pharmacol. Toxicol., 18.","DOI":"10.1186\/s40360-016-0102-9"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jacc.2014.06.009","article-title":"A Polypill Strategy to Improve Global Secondary Cardiovascular Prevention: From concept to reality","volume":"64","author":"Castellano","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ijcard.2015.12.015","article-title":"Effectiveness of fixed dose combination medication (\u2018polypills\u2019) compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries","volume":"205","author":"Webster","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1161\/CIRCOUTCOMES.115.001483","article-title":"Patients\u2019 and Providers\u2019 Perspectives of a Polypill Strategy to Improve Cardiovascular Prevention in Australian Primary Health Care: A qualitative study set within a pragmatic randomized, controlled trial","volume":"8","author":"Liu","year":"2015","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1177\/2047487314530382","article-title":"A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk","volume":"22","author":"Patel","year":"2015","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1177\/1753944718764588","article-title":"Polypill: An affordable strategy for cardiovascular disease prevention in low\u2013medium-income countries","volume":"12","author":"Serrano","year":"2018","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa1815359","article-title":"Polypill for Cardiovascular Disease Prevention in an Underserved Population","volume":"381","author":"Uzoije","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_32","first-page":"e13","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH)","volume":"41","author":"Burnier","year":"2023","journal-title":"J. Hypertens."},{"key":"ref_34","unstructured":"World Health Organization (2023, September 30). WHO Guideline for the Pharmacological Treatment of Hypertension in Adults. June 14, 2022. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/344424\/9789240033986-eng.pdf?sequence=9789240033981."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1600175","article-title":"Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease","volume":"374","author":"Lonn","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","article-title":"Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial","volume":"370","author":"Patel","year":"2007","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(97)05381-6","article-title":"Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators","volume":"350","author":"Staessen","year":"1997","journal-title":"Lancet"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1001\/archinte.160.2.211","article-title":"Chinese Trial on Isolated Systolic Hypertension in the Elderly. Systolic Hypertension in China (Syst-China) Collaborative Group","volume":"160","author":"Wang","year":"2000","journal-title":"Arch. Intern. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.amjmed.2011.12.010","article-title":"Angiotensin II Receptor Blocker-based Therapy in Japanese Elderly, High-risk, Hypertensive Patients","volume":"125","author":"Ogawa","year":"2012","journal-title":"Am. J. Med."},{"key":"ref_40","unstructured":"World Health Organization (2023, September 30). WHO Global Report on Hypertension: The Race against a Silent Killer. September 19, 2023. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240081062."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1751-7176.2008.07439.x","article-title":"Combination Therapy With Renin-Angiotensin-Aldosterone Receptor Blockers for Hypertension: How Far Have We Come?","volume":"10","author":"Weir","year":"2008","journal-title":"J. Clin. Hypertens."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/14779072.2022.2137490","article-title":"The role of blood pressure management in stroke prevention: Current status and future prospects","volume":"20","author":"Narita","year":"2022","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/jhh.2016.46","article-title":"High-dose calcium channel blocker (CCB) monotherapy vs combination therapy of standard-dose CCBs and angiotensin receptor blockers for hypertension: A meta-analysis","volume":"31","author":"He","year":"2017","journal-title":"J. Hum. Hypertens."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13643-020-01457-9","article-title":"Combining angiotensin receptor blockers with chlorthalidone or hydrochlorothiazide\u2013which is the better alternative? A meta-analysis","volume":"9","author":"Filipova","year":"2020","journal-title":"Syst. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1161\/HYPERTENSIONAHA.109.131466","article-title":"Differential Effects Between a Calcium Channel Blocker and a Diuretic When Used in Combination With Angiotensin II Receptor Blocker on Central Aortic Pressure in Hypertensive Patients","volume":"54","author":"Matsui","year":"2009","journal-title":"Hypertension"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/ajh.2010.240","article-title":"Urinary Albumin Excretion During Angiotensin II Receptor Blockade: Comparison of Combination Treatment With a Diuretic or a Calcium-Channel Blocker","volume":"24","author":"Matsui","year":"2011","journal-title":"Am. J. Hypertens."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/S0140-6736(23)00733-X","article-title":"Relationship between clinic and ambulatory blood pressure and mortality: An observational cohort study in 59 124 patients","volume":"401","author":"Staplin","year":"2023","journal-title":"Lancet"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/1470320310390404","article-title":"Efficacy of eplerenone added to renin-angiotensin blockade in elderly hypertensive patients: The Jichi-Eplerenone Treatment (JET) study","volume":"12","author":"Yano","year":"2011","journal-title":"J. Renin-Angiotensin-Aldosterone Syst."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/jhh.2015.125","article-title":"Combination therapy of renin\u2013angiotensin system inhibitors plus calcium channel blockers versus other two-drug combinations for hypertension: A systematic review and meta-analysis","volume":"31","author":"Lu","year":"2017","journal-title":"J. Hum. Hypertens."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/s41440-022-00923-2","article-title":"Angiotensin receptor\u2013neprilysin inhibitors for hypertension\u2014hemodynamic effects and relevance to hypertensive heart disease","volume":"45","author":"Kario","year":"2022","journal-title":"Hypertens. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1038\/s41440-023-01326-7","article-title":"Efficacy and safety of sacubitril\/allisartan for the treatment of primary hypertension: A phase 2 randomized, double-blind study","volume":"46","author":"Zhang","year":"2023","journal-title":"Hypertens. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1093\/eurheartj\/ehab499","article-title":"Sacubitril\u2013valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction","volume":"42","author":"Jackson","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1161\/CIRCULATIONAHA.118.037076","article-title":"24-Hour Blood Pressure-Lowering Effect of an SGLT-2 Inhibitor in Patients with Diabetes and Uncontrolled Nocturnal Hypertension: Results from the Randomized, Placebo-Controlled SACRA Study","volume":"139","author":"Kario","year":"2018","journal-title":"Circulation"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.118.037778","article-title":"Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial","volume":"139","author":"Fitchett","year":"2019","journal-title":"Circulation"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41440-023-01220-2","article-title":"Fluid homeostasis induced by sodium-glucose cotransporter 2 inhibitors: Novel insight for better cardio-renal outcomes in chronic kidney disease","volume":"46","author":"Masuda","year":"2023","journal-title":"Hypertens. Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.120.048740","article-title":"Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial","volume":"143","author":"Ye","year":"2021","journal-title":"Circulation"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2337\/dc18-2207","article-title":"Ambulatory Blood Pressure Reduction With SGLT-2 Inhibitors: Dose-Response Meta-analysis and Comparative Evaluation With Low-Dose Hydrochlorothiazide","volume":"42","author":"Georgianos","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11886-017-0853-y","article-title":"Strengths and Limitations of Using the Polypill in Cardiovascular Prevention","volume":"19","author":"Roy","year":"2017","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/S0140-6736(22)01847-5","article-title":"The polypill: From concept and evidence to implementation","volume":"400","author":"Yusuf","year":"2022","journal-title":"Lancet"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"p1847","DOI":"10.1136\/bmj.p1847","article-title":"The polypill and medicines access: Two decades and counting","volume":"382","author":"Rodgers","year":"2023","journal-title":"BMJ"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11906-019-0921-3","article-title":"Personalized Medicine and the Treatment of Hypertension","volume":"21","author":"Melville","year":"2019","journal-title":"Curr. Hypertens. Rep."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Hu, Y., Huerta, J., Cordella, N., Mishuris, R.G., and Paschalidis, I.C. (2023). Personalized hypertension treatment recommendations by a data-driven model. BMC Med Informatics Decis. Mak., 23.","DOI":"10.1186\/s12911-023-02137-z"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Visco, V., Izzo, C., Mancusi, C., Rispoli, A., Tedeschi, M., Virtuoso, N., Giano, A., Gioia, R., Melfi, A., and Serio, B. (2023). Artificial Intelligence in Hypertension Management: An Ace up Your Sleeve. J. Cardiovasc. Dev. Dis., 10.","DOI":"10.3390\/jcdd10020074"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41440-022-00997-y","article-title":"Digital Hypertension 2023: Concept, hypothesis, and new technology","volume":"45","author":"Kario","year":"2022","journal-title":"Hypertens. Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1097\/HJH.0000000000003175","article-title":"Simple predictive score for nocturnal hypertension and masked nocturnal hypertension using home blood pressure monitoring in clinical practice","volume":"40","author":"Narita","year":"2022","journal-title":"J. Hypertens."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2147\/IBPC.S74320","article-title":"Personalized medicine and treatment approaches in hypertension: Current perspectives","volume":"9","author":"Byrd","year":"2016","journal-title":"Integr. Blood Press. Control."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1053\/j.ajkd.2022.03.015","article-title":"Renal Denervation: A Review","volume":"80","author":"Townsend","year":"2022","journal-title":"Am. J. Kidney Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1093\/eurheartj\/ehad054","article-title":"Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)","volume":"44","author":"Barbato","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1093\/eurheartj\/ehab559","article-title":"Efficacy of a digital therapeutics system in the management of essential hypertension: The HERB-DH1 pivotal trial","volume":"42","author":"Kario","year":"2021","journal-title":"Eur. Heart J."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/23\/7226\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:26:42Z","timestamp":1760131602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/23\/7226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,22]]},"references-count":73,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["jcm12237226"],"URL":"https:\/\/doi.org\/10.3390\/jcm12237226","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,22]]}}}